Earnings Summary

Aurinia Pharmaceuticals Inc’s revenue jumped 58.59% since last year same period to $45.1Mn in the Q4 2023. On a quarterly growth basis, Aurinia Pharmaceuticals Inc has generated -17.28% fall in its revenue since last 3-months.

Aurinia Pharmaceuticals Inc’s net profit fell -3.18% since last year same period to $-26.88Mn in the Q4 2023. On a quarterly growth basis, Aurinia Pharmaceuticals Inc has generated -99.86% fall in its net profits since last 3-months.

Aurinia Pharmaceuticals Inc’s net profit margin jumped 34.94% since last year same period to -59.6% in the Q4 2023. On a quarterly growth basis, Aurinia Pharmaceuticals Inc has generated -141.61% fall in its net profit margins since last 3-months.

Aurinia Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.14 - a 12.5% jump from last quarter’s estimates.

Aurinia Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.14.

Aurinia Pharmaceuticals Inc’s earning per share (EPS) fell -5.56% since last year same period to -0.19 in the Q4 2023. This indicates that the Aurinia Pharmaceuticals Inc has generated -5.56% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Aurinia Pharmaceuticals Inc’s return on assets (ROA) stands at -0.11.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Aurinia Pharmaceuticals Inc’s return on equity (ROE) stands at -0.2.